New biomarker tests can help prevent devastating misdiagnoses. Beacon Hill should ensure that every patient can access them.

Research presented this week at the Alzheimer’s Association International Conference in London suggests that the use of blood ...

Just like we do for our hearts and our bodies, we need to have a multimodal approach to risk reduction of brain disease.” ...

New studies point to the power of testing for and treating tau, a protein that builds up in Alzheimer’s disease, instead of ...

"Alzheimer's disease impacts too many people, more than breast cancer and prostate cancer combined." ...

"Good candidates are individuals who are identified as having cognitive impairment distinct from normal aging via abnormal ...

Alzheimer's research is moving in new directions, finding ways to make testing much more accessible, and offering more ...

Nearly 7 million Americans are living with Alzheimer's disease and that number is projected to rise to nearly 13 million.

A 2026 JAMA study found the Alzheimer's blood test p-tau217 predicts cognitive impairment risk up to a decade early in ...

Prof Dan Martin said overall care at the hospital would become better thanks to the volume of clinical research The biggest hospital in south-west England has more patients involved in clinical trials ...

Impaired memory and thinking are the most common symptoms associated with a dementia diagnosis. But noncognitive symptoms can ...

"By bringing Alzheimer's blood-based biomarker testing into primary care, we can help patients and their clinicians get answers sooner." ...